Search Results | Blood | American Society of Hematology

1-20 of 158

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Betty K. Hamilton, Lisa A. Rybicki, Taylor Lucas, Donna Corrigan, Matt Kalaycio, Rabi Hanna, Seth J Rotz, Robert M. Dean, Aaron T. Gerds, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Edward A. Copelan, Navneet S. Majhail

Blood (2021) 138 (Supplement 1): 99.

DOI: https://doi.org/10.1182/blood-2021-149686

Published: 2021

Journal Articles

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

John Mascarenhas, Aaron T. Gerds, Arianna Kee, Jonathan K. Kish, Pranav Abraham, Alexandrina Balanean, Jose Alberto Nadal, Djibril Liassou, Bruce A. Feinberg, Ali McBride, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1980.

DOI: https://doi.org/10.1182/blood-2021-145573

Published: 2021

Journal Articles

Co-Occurrence of MDS with MGUS Represents a Unique Disease Entity with Specific Molecular Phenotype and Potential Improved Clinical Outcome

Tariq Kewan, Ramsha Ahmed, Carmelo Gurnari, Waled Bahaj, Simona Pagliuca, Yogenthiran Saunthararajah, Bhumika J. Patel, Sudipto Mukherjee, Aaron T. Gerds, Anjali Advani, Valeria Visconte, Jaroslaw P. Maciejewski, Hetty E. Carraway

Blood (2021) 138 (Supplement 1): 1529.

DOI: https://doi.org/10.1182/blood-2021-151858

Published: 2021

Journal Articles

Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis

Stephen T. Oh, Aaron T. Gerds, Ruben A. Mesa, Vikas Gupta, Mei Huang, Sunhee Ro, Bryan Strouse, Barbara Jane Klencke, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3638.

DOI: https://doi.org/10.1182/blood-2021-146623

Published: 2021

Journal Articles

A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia

John Mascarenhas, Prithviraj Bose, Jean-Jacques Kiladjian, Ruben A. Mesa, Aaron T. Gerds, Vikas Gupta, Claire N. Harrison, Abdulraheem Yacoub, Valentín Garcia Gutierrez, Alessandro M. Vannucchi, Christof Scheid, Patricia Velez Tenza, Sarah A Buckley, Karisse Roman-Torres, Stephen T. Oh, Marta Sobas, David Lavie, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3639.

DOI: https://doi.org/10.1182/blood-2021-146675

Published: 2021

Journal Articles

Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia

John Mascarenhas, Claire N. Harrison, Aaron T. Gerds, Josef T. Prchal, Raajit Rampal, Sarah A Buckley, Adam R Craig, Jennifer A. Smith, John Volpone, Karisse Roman-Torres, Ruben A. Mesa

Blood (2021) 138 (Supplement 1): 3640.

DOI: https://doi.org/10.1182/blood-2021-151395

Published: 2021

Journal Articles

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2021) 138 (Supplement 1): 3647.

DOI: https://doi.org/10.1182/blood-2021-148668

Published: 2021

Journal Articles

Long-Term Treatment with Pacritinib on a Compassionate Use Basis in Patients with Advanced Myelofibrosis

Claire N. Harrison, Abdulraheem Yacoub, Bart L. Scott, Adam J. Mead, Aaron T. Gerds, Jean-Jacques Kiladjian, Ruben A. Mesa, Miklos Egyed, Christof Scheid, Valentín Garcia Gutierrez, Sarah A Buckley, Kris Kanellopoulos, John Mascarenhas

Blood (2021) 138 (Supplement 1): 3649.

DOI: https://doi.org/10.1182/blood-2021-148793

Published: 2021

Journal Articles

The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study

Jeanne M. Palmer, Ruben A. Mesa, Stephen T. Oh, Raajit Rampal, Sarah A Buckley, Karisse Roman-Torres, Srdan Verstovsek, John Mascarenhas, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Claire N. Harrison, Prithviraj Bose, Adam R Craig, Aaron T. Gerds

Blood (2021) 138 (Supplement 1): 3628.

DOI: https://doi.org/10.1182/blood-2021-144505

Published: 2021

Journal Articles

Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis

Jennifer O'Sullivan, Aaron T. Gerds, Claire N. Harrison, Stephen T. Oh, Angela Hamblin, Sarah A Buckley, Alan F. List, Adam J. Mead

Blood (2021) 138 (Supplement 1): 3584.

DOI: https://doi.org/10.1182/blood-2021-149666

Published: 2021

Journal Articles

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Brent Wood, Jae H Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark R. Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba

Blood (2021) 138 (Supplement 1): 3397.

DOI: https://doi.org/10.1182/blood-2021-145529

Published: 2021

Journal Articles

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Leland Metheny, III, Ronald M. Sobecks, Christina Cho, Paolo F. Caimi, Navneet S. Majhail, Folashade Otegbeye, Kirsten M Boughan, Brenda W. Cooper, Erin Galloway, Molly Gallogly, Ehsan Malek, Benjamin Tomlinson, Aaron T. Gerds, Betty K. Hamilton, Matt Kalaycio, Sergio A Giralt, Marcos J.G. de Lima

Blood (2021) 138 (Supplement 1): 2899.

DOI: https://doi.org/10.1182/blood-2021-153041

Published: 2021

Journal Articles

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Claire N. Harrison, John Mascarenhas, Pranav Abraham, Arianna Kee, Jose Alberto Nadal, Alexandrina Balanean, Ali McBride, Jonathan K. Kish, Djibril Liassou, Bruce A. Feinberg, Aaron T. Gerds

Blood (2021) 138 (Supplement 1): 3059.

DOI: https://doi.org/10.1182/blood-2021-145569

Published: 2021

Journal Articles

A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study)

Aaron T. Gerds, Ruben A. Mesa, John M. Burke, Michael R. Grunwald, Brady Lee Stein, Robyn Scherber, Jingbo Yu, J.E. Hamer-Maansson, Stephen Oh

Blood (2021) 138 (Supplement 1): 239.

DOI: https://doi.org/10.1182/blood-2021-148509

Published: 2021

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Blood (2021) 138 (Supplement 1): 139.

DOI: https://doi.org/10.1182/blood-2021-148682

Published: 2021

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)

Blood (2021) 138 (Supplement 1): 386.

DOI: https://doi.org/10.1182/blood-2021-148210

Published: 2021

Journal Articles

Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production

Blood (2021) 138 (Supplement 1): 142.

DOI: https://doi.org/10.1182/blood-2021-148995

Published: 2021

Journal Articles

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Blood (2021) 138 (5): 387–400.

DOI: https://doi.org/10.1182/blood.2020008812

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

John Mascarenhas, MD, Brian Higgins, Doreen Anders, Kate Burbury, MD, Tarec Christoffer El-Galaly, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Bruno Kovic, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD

Blood (2020) 136 (Supplement 1): 29–31.

DOI: https://doi.org/10.1182/blood-2020-135868

Published: 2020

Journal Articles

A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Blood (2020) 136 (Supplement 1): 33–35.

DOI: https://doi.org/10.1182/blood-2020-139412

Published: 2020

2 3 4 5

NARROW

Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

Co-Occurrence of MDS with MGUS Represents a Unique Disease Entity with Specific Molecular Phenotype and Potential Improved Clinical Outcome

Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis

A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia

Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Long-Term Treatment with Pacritinib on a Compassionate Use Basis in Patients with Advanced Myelofibrosis

The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study

Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis

A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study)

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)

Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only